乌龙制药 URGN 深 沪
等待开盘 11-05 09:30:00 美东时间
19.81
-0.810
-3.93%
华盛通- 最 高20.58
- 今 开20.27
- 成交量 88.13万股
- 最 低 19.50
- 昨 收 20.62
- 总市值 9.16亿
- 52周最高 21.71
- 市盈率 静 --
- 换手率 1.90%
- 52周最低 3.42
- 委 比 -95.55%
- 总股本 4626.41万
- 历史最高 69.568
- 量 比 1.01
- 振 幅 5.24%
- 历史最低 3.42
- 每 手 1
- 风险率 4.12%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference
UroGen Pharma Ltd. announced its participation in the Guggenheim Securities Healthcare Innovation Conference on November 11, 2025, in Boston, featuring a presentation and investor meetings. The company, focused on innovative treatments for urothelial and specialty cancers, will also provide a webcast available on its Investor Relations website for 90 days.
11-04 13:00
美股大行评级 | 买入！Fermi、Neptune获多家大行首予评级；伯克希尔哈撒韦罕见地获得“卖出”评级；摩根大通上调苹果目标价升至290美元
今日重点评级关注：Guggenheim：上调Neumora Therapeutics评级至"买入"，目标价14美元；韦德布什：上调Fate Therapeutics评级至"跑赢大市"，目标价从5美元升至7美元
10-28 10:08
HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $40 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $40 price target.
10-27 23:22
Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026
UroGen Pharma announced that the CMS has assigned a permanent HCPCS Level II J Code, J9282, for ZUSDURI (mitomycin) for intravesical solution, the first and only FDA-approved treatment for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The J Code, effective January 1, 2026, aims to streamline billing and claims submission across care settings, simplifying reimbursement processes for providers and improving...
10-27 12:00
美股大行评级 | 潜在涨幅1176.6%！Ascendiant Capital上调Society Pass目标价至18美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从15美元升至18美元；Ascendiant Capital：维持Surgepays"买入"评级，目标价从9美元升至9.5美元
10-06 08:35
UroGen Publishes Comprehensive Review Of ZUSDURI For Recurrent LG-IR Non–Muscle-Invasive Bladder Cancer, Titled: "Review of UGN-102: A Reverse Thermal Gel Containing Mitomycin for the Treatment of Recurrent, Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer"
UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company focused on developing and commercializing innovative solutions for urothelial and specialty cancers, today announced the publication of a comprehensive review of the
10-02 20:05
ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer
UroGen Pharma announced the publication of a comprehensive review of ZUSDURI (mitomycin) for intravesical solution, the first FDA-approved non-surgical treatment for recurrent low-grade, intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC). Clinical trials showed complete response rates between 64.8% and 79.6%, with durable responses lasting up to 42.1 months. The treatment has a manageable safety profile, mainly affecting the lower...
10-02 12:00
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma Ltd. announced the grant of inducement restricted stock units (RSUs) to 40 new employees, as an incentive for their employment. These RSUs, totaling up to 67,700 ordinary shares, will vest equally over three years. The RSUs are subject to UroGen’s 2019 Inducement Plan and were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The new team members will support the commercialization of Jelmyto and ZUSDURI and the development ...
09-08 12:00
UroGen Pharma to Present at Upcoming Investor Conferences
UroGen Pharma Ltd. announced its participation in three investor conferences in September: the Wells Fargo Healthcare Conference on September 3rd, the Cantor Fitzgerald Global Healthcare Conference on September 4th, and the H.C. Wainwright 27th Annual Global Healthcare Conference on September 8th. All events will be conducted as Fireside Chats and webcasts will be available on the company’s Investor Relations website, with replays accessible for ...
08-21 12:00
Piper Sandler Initiates Coverage On UroGen Pharma with Overweight Rating, Announces Price Target of $36
Piper Sandler analyst Kelsey Goodwin initiates coverage on UroGen Pharma (NASDAQ:URGN) with a Overweight rating and announces Price Target of $36.
08-19 20:04
